Skip to content
‹ Back to IndustriesSciences

NASA Joins the International Effort to Learn More About Norway’s Auroral Cusp

A solar wind of ionized particles from the sun is constantly blowing through the solar system. Earth’s only protection from this wind is its magnetic field, which emerges from the north pole, wraps around the earth, and re-enters the earth at the south pole. Mars has no atmosphere because, after it lost its protective magnetic…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · ·
Share

Key takeaways

01

A solar wind of ionized particles from the sun is constantly blowing through the solar system.

02

Earth’s only protection from this wind is its magnetic field, which emerges from the north pole, wraps around the earth, and re-enters the earth at the south pole.

03

Mars has no atmosphere because, after it lost its protective magnetic…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

A solar wind of ionized particles from the sun is constantly blowing through the solar system. Earth’s only protection from this wind is its magnetic field, which emerges from the north pole, wraps around the earth, and re-enters the earth at the south pole. Mars has no atmosphere because, after it lost its protective magnetic field, the solar winds literally blew the atmosphere away. The earth’s active magnetic field is what keeps the same thing from happening here, and life disappearing from earth.

Near the poles, however, where the magnetic field bends in toward the earth, the solar wind can come into contact with the atmosphere, heating up the atmosphere and causing the auroras as the ionized particles bombard air molecules. According to Eureka Alert!, “North of Norway over the Norwegian and Greenland Seas, the magnetic bubble surrounding the Earth dips inward, allowing space particles to funnel in toward the planet.” This cusp, where energy from the solar wind “heats the atmosphere by hundreds of degrees,” is actually visible to the naked eye in November and December.

This is why “eight missions with 11 rockets will launch from two sites in Norway—Andøya Space Center and Svalbard Rocket Range” around this time in 2018 and 2019. “The first mission—a NASA mission called the Auroral Zone Upwelling Rocket Experiment, or AZURE—launches in March 2018.” NASA will also launch “the Visualizing Ion Outflow via Neutral Atom Sensing-2 experiment or VISIONS-2” in December 2018. There will also be the “Norwegian Investigation of Cusp Irregularities-5 or ICI-5 mission in December 2019.”

The Eureka Alert website further explains, “In addition to AZURE, VISIONS-2 and ICI-5, other NASA Grand Challenge missions are the Twin Rockets to Investigate Cusp Electrodynamics or TRICE-2 (led by the University of Iowa, launching December 2018), The Cusp Alfven and Plasma Electrodynamics Rocket or CAPER-2 (led by Dartmouth University, launching January 2019), and the Cusp-Region Experiment or C-REX 2 (led by the University of Alaska, launching November 2019), which also includes three Canadian instruments from the University of Calgary (also flying on VISIONS-2).” Furthermore, “The Japan Aerospace Exploration Agency (JAXA) will fly the SS-520-3 in January 2019, which investigates the ion outflow mechanism in the cusp.”

The next year will be exciting for both atmospheric and space science at the international level. By learning more about this unique feature in our atmosphere created by the earth’s magnetic field, we will learn more about the solar wind, how the solar wind interacts with the atmosphere, and how our magnetic field protects life on earth. So, stay tuned to science news over the next several years as new data surfaces and more knowledge about the cusp is created.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte's December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own financial outlook but only 41% optimistic about the global economy, the mood the program is built for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512